Abstract
Macrolide antibiotics are widely prescribed for the treatment of respiratory tract infections; however, the increasing prevalence of macrolide-resistant pathogens is a public health concern. Therefore, the development of new macrolide derivatives with activities against resistant pathogens is urgently needed. A series of novel 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides has been synthesized from erythromycin A. These compounds have shown very promising in vitro and in vivo antibacterial activities against key respiratory pathogens including erythromycin-susceptible/resistant strains.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Anti-Bacterial Agents / chemical synthesis
-
Anti-Bacterial Agents / chemistry*
-
Anti-Bacterial Agents / pharmacology*
-
Crystallography, X-Ray
-
Drug Resistance, Bacterial
-
Erythromycin / analogs & derivatives
-
Erythromycin / chemical synthesis
-
Erythromycin / pharmacology
-
Haemophilus Infections / drug therapy
-
Haemophilus influenzae / drug effects*
-
Halogenation
-
Humans
-
Ketolides / chemical synthesis
-
Ketolides / chemistry*
-
Ketolides / pharmacology*
-
Microbial Sensitivity Tests
-
Models, Molecular
-
Respiratory Tract Infections / drug therapy
-
Respiratory Tract Infections / microbiology*
-
Staphylococcal Infections / drug therapy
-
Staphylococcus / drug effects*
Substances
-
Anti-Bacterial Agents
-
Ketolides
-
Erythromycin